RMC-6236-304 (RASolute 304):A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Objective

Clinical Trial Details

Principal Investigator(s)
Heidi McKean, MD

Clinical Trial Categories

  • Cancer
  • Pancreatic Cancer
Contact
Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org

Location

  • Avera Cancer Institute — Mitchell
    605 N Foster St
    Mitchell, SD 57301
    Main: 605-995-5756
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000